Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

Cassava Sciences ( ($SAVA) ) has released its Q4 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A.

“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. “We are pleased to enter into a license agreement with Yale University, based on the research of Dr ...

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025 License agreement brings potential in a new ...